Deng Yiming, Yao Yunchu, Tong Xu, Yin Yue, Wang Anxin, Zhang Yijun, Jia Baixue, Huo Xiaochuan, Luo Gang, Ma Ning, Mo Dapeng, Song Ligang, Sun Xuan, Gao Feng, Chen Duanduan
Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing, China.
Front Neurol. 2023 Mar 16;14:1087816. doi: 10.3389/fneur.2023.1087816. eCollection 2023.
The effects of angioplasty on intracranial atherosclerotic disease (ICAD)-related acute large-vessel occlusion stroke (LVOS) are unknown. We analyzed the efficacy and safety of angioplasty or stenting for ICAD-related LVOS and the optimal treatment duration.
Patients with ICAD-related LVOS from a prospective cohort of the Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemia Stroke registry were classified as follows: the early intraprocedural angioplasty and/or stenting (EAS) group was defined as the strategy using angioplasty or stenting without mechanical thrombectomy (MT) or one attempt of MT; the non-angioplasty and/or stenting (NAS) group, MT procedure without any angioplasty; and the late intraprocedural angioplasty and/or stenting (LAS) group, using same angioplasty techniques following two or more passes of MT. The primary endpoint was the modified Rankin Scale (mRS) score at 90 days. Other efficacy outcomes included mRS scores 0-1, mRS 0-2, and successful recanalization. Death within 90 days, and symptomatic ICH were safety endpoints. We use propensity score method to diminish the effect of treatment-selection bias. The odds ratio of recanalization rate and mRS score among EAS, NAS, and LAS groups were examined by unadjusted and adjusted logistic regression analysis among unweighted samples and inverse probability of treatment weighting (IPTW) samples.
We divided 475 cases into three groups. Functional outcomes at 90 days were better in the EAS group than in the NAS and LAS groups. The proportion of mRS 0-1, mRS 0-2, and successful recanalization cases were the highest in the EAS group. However, after IPTW, mortality rate among the three groups were similar (EAS vs. NAS vs. LAS: 19.0 vs. 18.1 vs. 18.7%, = 0.98) as well as symptomatic intracranial hemorrhage within 24 h however, mortality rate and symptomatic intracranial hemorrhage among the three groups were similar. Logistic regression analysis in unweighted samples and IPTW samples both showed that EAS group had better outcomes. IPTW-adjusted logistic regression analysis demonstrated that the EAS group had better outcomes (mRS 0-1) than the NAS group (adjusted odds ratio [aOR], 0.55; 95% confidence interval [CI]: 0.34-0.88, = 0.01) and LAS (aOR, 0.39; 95% CI: 0.22-0.68, = 0.001).
Angioplasty and/or stenting should be performed at an early stage for ICAD-related acute LVOS.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03370939.
血管成形术对颅内动脉粥样硬化疾病(ICAD)相关的急性大血管闭塞性卒中(LVOS)的影响尚不清楚。我们分析了血管成形术或支架置入术治疗ICAD相关LVOS的疗效和安全性以及最佳治疗持续时间。
来自急性缺血性卒中血管内治疗关键技术与急诊工作流程改进前瞻性队列中ICAD相关LVOS患者被分类如下:早期术中血管成形术和/或支架置入术(EAS)组定义为使用血管成形术或支架置入术而不进行机械取栓(MT)或单次MT尝试的策略;非血管成形术和/或支架置入术(NAS)组,进行无任何血管成形术的MT手术;晚期术中血管成形术和/或支架置入术(LAS)组,在进行两次或更多次MT后使用相同的血管成形术技术。主要终点是90天时的改良Rankin量表(mRS)评分。其他疗效指标包括mRS评分0 - 1、mRS 0 - 2和成功再通。90天内死亡和症状性颅内出血是安全终点。我们使用倾向评分法来减少治疗选择偏倚的影响。通过未加权样本和治疗逆概率加权(IPTW)样本中的未调整和调整逻辑回归分析,检验EAS、NAS和LAS组之间再通率和mRS评分的比值比。
我们将475例患者分为三组。EAS组90天时的功能结局优于NAS组和LAS组。EAS组中mRS 0 - 1、mRS 0 - 2和成功再通病例的比例最高。然而,IPTW后,三组的死亡率相似(EAS组 vs. NAS组 vs. LAS组:19.0% vs. 18.1% vs. 18.7%,P = 0.98),24小时内症状性颅内出血情况也是如此,然而,三组的死亡率和症状性颅内出血情况相似。未加权样本和IPTW样本中的逻辑回归分析均显示EAS组结局更好。IPTW调整后的逻辑回归分析表明,EAS组的结局(mRS 评为0 - 1)优于NAS组(调整后的比值比[aOR],0.55;95%置信区间[CI]:0.34 - 0.88,P = 0.01)和LAS组(aOR,0.39;95% CI:0.22 - 0.68,P = 0.001)。
对于ICAD相关的急性LVOS,应尽早进行血管成形术和/或支架置入术。